Eleanor Crane: I need to ask you something before we get going — when you think about the immune system, do you picture it as something that solved a problem, or something that's managing one?
Ben Okonkwo: Hm — managing, definitely. Though I didn't always think of it that way.
Eleanor Crane: Because the version most of us carry around — and I held this one for a long time — is that your body figured out how to distinguish self from non-self, and that's the end of it. Clean. Done. But that's not the actual story.
Ben Okonkwo: Right — the actual story is that healthy people, right now, are carrying autoreactive lymphocytes that survived the selection process in the Thymus and the Bone Marrow. Not because the process failed. Because the process structurally cannot catch everything.
Eleanor Crane: That's — yeah. And that's the thing I want to name clearly, because it's easy to slide past it. The Thymus runs what's called negative selection — T cells that bind too strongly to self-antigens are deleted, apoptosis, gone. But the self-antigens the Thymus can actually present are a subset. It's running a test it can only partially write.
Ben Okonkwo: And the Bone Marrow does the same for B cells — self-reactive ones get edited or deleted, but with the same ceiling. You can only screen against what you have in the room.
Eleanor Crane: Here's the plain-language version — imagine training a security force, and at the end of every training cycle you remove anyone who attacks the furniture. Reasonable. Except some recruits graduated before that particular test ran. They're out in the building. And the building's designers knew they would be.
Ben Okonkwo: That last part is the part that keeps landing differently each time I think about it — the designers knew. The incompleteness isn't a flaw that accrued over time. It's load-bearing.
Eleanor Crane: And what does the system build on top of that? That's what I want to pull on — because there has to be an answer, given that most of us are not currently attacking ourselves.
Ben Okonkwo: There is — and it's a whole second layer. But I think we need to sit with the incompleteness first, because once you understand that the gap is intentional, the backup systems stop looking like redundancy and start looking like the primary architecture.
Eleanor Crane: But the primary architecture still has to start somewhere concrete — and what the Thymus is actually doing mechanically is where the real surprise is, I think.
Ben Okonkwo: Right — so walk through it. Developing T cells arrive in the Thymus and get tested. Bind too strongly to a self-antigen — you die, apoptosis, negative selection. Bind too weakly — you also die. Only the middle range survives. That's the filter.
Eleanor Crane: Which is already a strange design.
Ben Okonkwo: It is. And then AIRE comes in — Autoimmune Regulator — which is, I mean, when I first read the mechanism I had to sit with it. Thymic epithelial cells use AIRE to actually express antigens from peripheral tissues. Liver antigens. Pancreatic antigens. Thyroid. Inside the thymus. So T cells that would attack those tissues can be caught and deleted before they ever leave.
Eleanor Crane: Wait — the thymus is impersonating the pancreas?
Ben Okonkwo: Essentially, yes. That's not a metaphor, that's the mechanism. AIRE enables ectopic expression of tissue-restricted antigens. It's a genuine workaround for the fact that the thymus is one organ trying to preview the whole body.
Eleanor Crane: And — and this is the part I want to press on — workaround is the right word. Not solution. Because the body is far too complex for any single organ to preview every tissue antigen. AIRE broadens the scope, but it doesn't close the gap.
Ben Okonkwo: No. It doesn't. That's the structural limit. Some self-antigens are simply never represented in the thymus — and so the T cells that would recognize them pass every checkpoint. They graduate. They circulate.
Eleanor Crane: Which brings me to the bone marrow — because there's something happening there that I did not expect, actually. B cells. The second-chance mechanism.
Ben Okonkwo: Receptor editing.
Eleanor Crane: Self-reactive B cells in the bone marrow don't just get deleted outright — they get an opportunity to rearrange their receptor. Literally reorganize their own identity to avoid recognizing self. And only if that fails do they get deleted. That's not a checkpoint. That's — the immune system negotiating with itself.
Ben Okonkwo: And it tells you something important about the architecture — even central tolerance isn't a single binary gate. It's multi-step, it's iterative. The thymus deletes or retains, the bone marrow edits or deletes. Which means the question of what escapes isn't simple, because there are multiple points at which something can slip through. So — what actually catches what both organs miss?
Eleanor Crane: That's exactly where I want to go — because the answer involves a population of cells that essentially exist to manage the consequences of this structural incompleteness. And the story of how we even figured out they existed is its own thing.
Ben Okonkwo: The cells that catch what the Thymus and Bone Marrow miss — that's Regulatory T cells. Tregs. How they get recruited in the first place is almost counterintuitive, and that's what fascinates me.
Ben Okonkwo: The same middle-range affinity that lets a T cell survive thymic selection — not strong enough to be deleted, not weak enough to be ignored — that's actually the binding profile that can tip a cell into becoming a Treg. The peacekeeper and the potential threat start from the same place on the spectrum.
Eleanor Crane: Which is — I mean, that's the Goldilocks problem, and naming it that almost undersells how strange it is. Because what you're describing is a system where the ingredient for self-suppression and the ingredient for autoimmunity are, at origin, the same cell.
Ben Okonkwo: Exactly the same. And what makes it land for me — there's a woman, let's call her Mara, sitting in a clinic getting a blood draw. She's been told she has a Treg deficiency. Her doctors can measure her CD25 levels — that's the IL-2 receptor alpha-chain, the surface marker Shimon Sakaguchi identified in 1995 as the signature of suppressive CD4+ T cells. They can see it. What they cannot tell her is whether the Tregs she still has are holding the line or already losing it.
Eleanor Crane: That's the measurement gap that actually costs something.
Ben Okonkwo: And Sakaguchi's 1995 finding is what made that gap visible in the first place — he disrupts this one tolerance mechanism, CD25-positive suppressive cells, and what you get isn't one autoimmune disease. You get multiple. Thyroiditis, gastritis, diabetes. One marker, one disruption, the whole peripheral net tears.
Eleanor Crane: Wait — multiple diseases from a single disruption?
Ben Okonkwo: Multiple. Which told us something foundational — Tregs aren't organ-specific guardians. They're doing continuous suppression across tissues, system-wide. Remove them, and the autoreactive cells that graduated from the Thymus find nothing stopping them.
Eleanor Crane: And then 2003 — FOXP3. The forkhead transcription factor that actually defines what a Treg is at the molecular level. That felt like a confirmation, not a discovery. Like the biology finally handed us the receipt for what Sakaguchi had already seen.
Ben Okonkwo: It is a confirmation in one sense — FOXP3 gives you the molecular identity of the lineage, which is enormous. But here's where I'd slow down, because FOXP3 doesn't resolve the Goldilocks problem. It tells us what a mature Treg looks like. It doesn't tell us where exactly on the affinity spectrum a developing cell commits to that path versus, say, becoming pathogenic. That line is still — I mean, we don't have a clean answer.
Eleanor Crane: And that's what I keep wanting to put in front of a listener — the question isn't whether Tregs work. They do. Sakaguchi proved what happens when they're gone. The question is whether a Treg that's present is actually functioning, or whether the same cell, same marker, same FOXP3 expression, is about to flip.
Ben Okonkwo: Which is precisely what Mara's doctors can't answer from a blood draw.
Eleanor Crane: And what we haven't touched yet is why a Treg deficiency shows up differently in different people. HLA haplotypes, molecular mimicry, the multi-trigger picture. That's a whole layer that makes this measurement problem worse, not better.
Ben Okonkwo: And that layer — HLA haplotypes — is actually where the clean single-mechanism story collapses entirely. Because HLA variants don't just influence disease risk. They govern which self-antigens get presented during thymic selection in the first place. So two people can have almost identical Treg counts, identical FOXP3 expression, and one develops type 1 diabetes, one develops lupus, one develops MS — and the difference is upstream, in the MHC machinery.
Eleanor Crane: Wait — so the genetic susceptibility is baked into the same mechanism that runs the selection process?
Ben Okonkwo: Yes. HLA haplotypes determine what gets shown to developing T cells in the thymus — that means specific HLA variants are directly tied to differential risk across rheumatoid arthritis, Graves' disease, lupus, MS, type 1 diabetes. Not as correlation. As mechanism. The same MHC machinery that shapes tolerance also sets the floor for how badly it can fail.
Eleanor Crane: And that's — I mean, that should change how we think about why molecular mimicry looks so compelling as a story. Because if your HLA variant already narrows which antigens got presented, an infection that looks like one of those antigens isn't random bad luck.
Ben Okonkwo: It's targeted bad luck, almost. But — and I want to name this carefully — mimicry is documented. The structural resemblance between foreign antigens and self-antigens, that's real. What the sources are explicit about is that mimicry alone doesn't explain most autoimmune disease. The evidence won't carry that weight.
Eleanor Crane: So what else is carrying the weight?
Ben Okonkwo: Bystander activation, persistent antigenic stimulation, microbiota — all operating simultaneously with mimicry. And we don't actually know their relative contributions. That's not a hedge, that's the state of the literature. We're looking at multiple pathways and we can't rank them.
Eleanor Crane: Which means — actually, no, I want to push on this — if we can't rank the pathways, do we even know whether any given autoimmune disease is primarily a failure of central tolerance or peripheral tolerance? Or both?
Ben Okonkwo: Genuinely open question. The sources don't converge. For type 1 diabetes, molecular mimicry and peripheral failure are both implicated. For lupus, the HLA link is strong but the mechanism differs. There's no single dominant answer across disease types.
Eleanor Crane: That fractures the preventive logic entirely.
Ben Okonkwo: It does. And you see it in applied form most recently with the SARS-CoV-2 mRNA vaccines — encapsulated in lipid nanoparticles — which brought vaccine-induced immune dysregulation into public conversation. Because individuals with HLA haplotypes prone to intense inflammatory responses may carry elevated risk, and there is no population-scale screen for that.
Eleanor Crane: Hold on — elevated risk for which individuals, and how would you even identify them before vaccination?
Ben Okonkwo: That's exactly the problem. HLA-driven susceptibility is real at the population level — you see it cluster statistically in autoimmune outcomes post-vaccination. But individual prediction before the fact? We can't do it at scale. So adjuvant selection, post-vaccination monitoring — those remain open design questions, not solved ones.
Eleanor Crane: And that's — I mean, this is the same measurement gap as Mara's blood draw, just in a different setting. We can see the group risk. We cannot see the individual.
Ben Okonkwo: Right — and the question that doesn't resolve is whether population-level benefit justifies unmonitored risk in genetically high-risk subgroups. That's not answered. It's not close to answered.
Eleanor Crane: So the hard version of what we're saying is that autoimmune disease isn't one failure — it's a convergence. HLA sets the genetic floor, an environmental trigger pulls the thread, and the tolerance systems that were always incomplete have nothing left to catch it.
Ben Okonkwo: And no single mechanism is dominant. That's the thing we resist saying because it's unsatisfying — but it's what the evidence actually shows.
Eleanor Crane: And that's the thread I can't put down — that the same unresolved measurement gap, the one that means we can't tell whether Mara's Tregs are holding, is the exact same gap that means we can't certify a vaccine antigen is safe for every recipient. It's not two problems. It's one problem wearing different faces. We don't know where any individual's tolerance threshold sits. We don't know when it's about to fail. And until we do, population-level benefit and individual-level risk are just — they're living in different conversations.
Ben Okonkwo: And I think the next leap probably isn't another mechanism to discover. The architecture is largely described. What we're missing is a real-time readout. Something that can tell you, from an individual's blood, right now, whether their peripheral tolerance is stable or eroding. Not a population signal. An individual one.
Eleanor Crane: We don't have that tool.
Ben Okonkwo: No. We genuinely don't. And I can't tell you when we will. That's the honest place — the Thymus does what it can, the Tregs do what they can, and we still have no way to read the margin for any specific person before something goes wrong.
